Yong Huang

ORCID: 0000-0001-5953-6908
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • scientometrics and bibliometrics research
  • Advanced Text Analysis Techniques
  • Complex Network Analysis Techniques
  • Topic Modeling
  • Scientific Computing and Data Management
  • Biomedical Text Mining and Ontologies
  • Data Quality and Management
  • Cancer Immunotherapy and Biomarkers
  • Cancer Cells and Metastasis
  • Research Data Management Practices
  • Lung Cancer Treatments and Mutations
  • Academic Writing and Publishing
  • Open Source Software Innovations
  • Cancer Mechanisms and Therapy
  • Gastrointestinal Tumor Research and Treatment
  • Bioinformatics and Genomic Networks
  • Information Retrieval and Search Behavior
  • RNA modifications and cancer
  • Expert finding and Q&A systems
  • Stroke Rehabilitation and Recovery
  • Advanced Computing and Algorithms
  • High-Temperature Coating Behaviors
  • Customer Service Quality and Loyalty
  • Gastric Cancer Management and Outcomes
  • Computational and Text Analysis Methods

Wuhan University
2013-2024

Shandong First Medical University
2008-2024

Shandong Tumor Hospital
2008-2024

Lanzhou Jiaotong University
2024

Shandong University
2014-2024

Jiangnan University
2024

Third People's Hospital of Hefei
2017-2023

Indiana University Bloomington
2018-2019

Chinese People's Liberation Army
2017

Chang'an University
2007

Abstract The citation impact of a scientific publication is usually seen as one-dimensional concept. We introduce multidimensional framework for characterizing the publication. In addition to level impact, quantified by number citations received publication, we also conceptualize and operationalize depth breadth dependence independence proposed distinguishes between publications that have deep typically in relatively narrow research area, broad probably covering wider area research. It makes...

10.1162/qss_a_00109 article EN cc-by Quantitative Science Studies 2021-01-01

Apatinib, a highly selective VEGFR2 inhibitor, significantly improved efficacy versus placebo as third- and later-line treatment for advanced gastric cancer in phase 2 3 trials. This prospective, single-arm, multicenter IV AHEAD study was conducted to verify the safety of apatinib patients with or metastatic gastroesophageal adenocarcinoma after at least two lines systematic therapy clinical practice settings.

10.1186/s12916-023-02841-7 article EN cc-by BMC Medicine 2023-05-05

Tumor development is initiated by an accumulation of numerous genetic and epigenetic alterations that promote tumor initiation, invasion metastasis. Astrocyte elevated gene-1 [AEG-1; also known as Metadherin (MTDH) Lysine-rich CEACAM1 co-isolated (LYRIC)] has emerged in recent years a potentially crucial mediator malignancy, key converging point complex network oncogenic signaling pathways. AEG-1/MTDH multifunctional role been found to be involved the following cascades: i) The Ha-Ras...

10.3892/ol.2014.2231 article EN Oncology Letters 2014-06-05

Proliferation-associated nucleolar protein p120 (NOP2) has been proven to be a promising tumor cell maker, but it not specifically studied in colon cancer. This study aims investigate the role and action mechanism of NOP2 cancer.Fluorescence quantitative PCR western blot assays were used evaluate expression NOP2. siRNA was transfected into HCT116, LOVO, CCK-8 cells, transwell performed proliferation, migration, invasion. Transcriptome sequencing both knockdown negative control (NC) groups...

10.21037/tcr.2019.09.46 article EN Translational Cancer Research 2019-10-01

e20074 Background: This study aimed to evaluate the safety and efficacy of neoadjuvant camrelizumab combined with chemotherapy in patients resectable non-small cell lung cancer (NSCLC). Methods: In this single-arm phase II clinical trial, aged 18-75 pathologically confirmed stage IIIA-IIIB (T3-4N2) NSCLC without EGFR, ALK, ROS1 gene mutations were enrolled since December 2022. Patients assigned receive 3 cycles (200 mg) plus (nab-paclitaxel, 130 mg/m 2 or pemetrexed (for adenocarcinoma),...

10.1200/jco.2024.42.16_suppl.e20074 article EN Journal of Clinical Oncology 2024-06-01
Coming Soon ...